Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rebecca Christian Arend"'
Autor:
Jaclyn Wall, Nicole E. Caston, Gabrielle Betty Rocque, Rebecca Christian Arend, Jesse Sussell, Margaret Irene Liang
Publikováno v:
Journal of Clinical Oncology. 40:83-83
83 Background: Enrollment in Phase III clinical trials in gynecologic cancer patients has decreased by approximately 90% since 2011. Efforts to increase enrollment are needed. Previous research showed that not all eligible patients are approached, an
Autor:
Nicole E. Caston, Fallon Lalor, Jaclyn Wall, Jesse Sussell, Shilpen A. Patel, Courtney Williams, Andres Azuero, Rebecca Christian Arend, Margaret Irene Liang, Gabrielle Betty Rocque
Publikováno v:
Journal of Clinical Oncology. 40:85-85
85 Background: Most patients with cancer experience multi-leveled barriers to clinical trial participation, potentially including financial concerns due to the complexity surrounding trial-related insurance coverage. Our study sought to understand th
Autor:
Richard T. Penson, Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Shifra Fain Shmueli, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:TPS5606-TPS5606
TPS5606 Background: Ofranergene obadenovec (Ofra-vec, VB-111) is an anti-cancer gene based immune activator and targeted vascular disruptor. The dual mechanism of action triggers a broad antiangiogenic effect and induces of a tumor directed immune re
Autor:
David M. O'Malley, Rebecca Christian Arend, Naufil Alam, Ozan Ozgoren, Kimmie K. McLaurin, Grainne H. Long, Susana N. Banerjee
Publikováno v:
Journal of Clinical Oncology. 40:5552-5552
5552 Background: Tolerability is a key consideration when selecting a PARP inhibitor (PARPi) for ovarian cancer (OC). Here we expand on earlier work (Arend et al 2021) to further characterize real-world tolerability and dose modifications in US patie
Autor:
Rebecca Christian Arend, Bradley J. Monk, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson
Publikováno v:
Journal of Clinical Oncology. 39:TPS5599-TPS5599
TPS5599 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism of action that includes a broad antiangiogenic effect and induction of a tumor directed immune response. A phase II trial in patients wit